GlaxoSmithKline has no plans to delist Indian arm - executive
MUMBAI (Reuters) - GlaxoSmithKline Plc has no plans to delist its Indian consumer products arm GlaxoSmithKline Consumer Healthcare Ltd, David Redfern, chief strategy officer at Britain's biggest drugmaker, said on Monday.
GSK said earlier it planned to buy up to an additional 31.8 percent stake in the Indian unit for 52.2 billion rupees ($939 million).
The company has been expanding into both emerging markets and non-prescription consumer health - and in some cases a combination of the two.
The company, which plans to launch new variants of the flagship Horlicks brand in India, is looking to increase penetration of the product in the north and western regions of the country, Redfern said.
(Reporting by Kaustubh Kulkarni; Editing by Subhranshu Sahu)
- Thousands of Gaza civilians flee after Israeli warning |
- Russia threatens Ukraine after shell crosses border
- Three dead, two wounded in Pasadena, California shootings
- Teen survivor of Texas shootings says slain family members 'in much better place'
- REFILE-UPDATE 3-Thousands of Gaza civilians flee after Israeli warning
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video